Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 5M | 6M | 6M |
| Gross Profit | 4M | 4M | 4M | 6M | 5M |
| Operating Income | -5M | -5M | -7M | -9M | -13M |
| EBITDA | -5M | -5M | -6M | -8M | -13M |
| Net Income | -6M | -5M | -7M | -9M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.70
+1.19% today
1Y Change
-28.27%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zeo ScientifiX, Inc. (ZEOX) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $1.70 and down 28.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +12.5%, EPS growth of -16.2%, a dividend yield of 0.0%. What stands out right now is revenue +12.5%, EPS -16.2%, free cash flow +48.9% with operating margin -90.2% and ROIC 1796.1%. Valuation is more restrained than many high-expectation growth names at price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZEOX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZEOX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ZEOX Max Drawdown
-47.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ZEOX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.6M
-13.8% YoY
FY Net Income
-$12.8M
-43.4% YoY
Free Cash Flow
-$3.1M
+22.2% YoY
Revenue Growth
+12.5%
EPS Growth
-16.2%
Gross Margin
81.6%
Net Margin
-92.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 5M | 5M | 6M | 6M |
| Gross Profit | 4M | 4M | 4M | 6M | 5M |
| Operating Income | -5M | -5M | -7M | -9M | -13M |
| EBITDA | -5M | -5M | -6M | -8M | -13M |
| Net Income | -6M | -5M | -7M | -9M | -13M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 221K | 657K | 2M | 4M | 109K |
| Total Assets | 2M | 2M | 3M | 6M | 2M |
| Total Liabilities | 3M | 3M | 4M | 4M | 5M |
| Shareholder Equity | -1M | -2M | -1M | 2M | -3M |
| Total Debt | 110K | 13K | 693K | 1M | 827K |
| Net Debt | -111K | -644K | -1M | -3M | 719K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+15.3% YoY
Capital Expenditures
425K
+48.5% YoY
Free Cash Flow
3M
+22.2% YoY
Key ratios
Gross Margin
81.6%
Operating Margin
-90.2%
Net Margin
-92.3%
ROE
329.9%
Debt / Equity
-0.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.